Management of Malignant Hypertension

Definition and Pathophysiology

Malignant hypertension is a hypertensive emergency characterized by severe blood pressure elevation with acute hypertension-mediated organ damage, particularly advanced retinopathy, and involves breakdown of autoregulation due to arterial walls being continuously exposed to extremely high blood pressure levels, leading to myointimal proliferation and fibrinoid necrosis, according to the European Society of Cardiology 1, 2, 3
Pathophysiologically, it involves autoregulation failure, microcirculatory damage, and marked activation of the renin-angiotensin system, as stated by the European Heart Journal 1, 2

Key target organs affected include the heart, retina, brain, kidneys, and large arteries, as reported by the European Society of Cardiology 1
Advanced retinopathy is a hallmark finding, with flame-shaped hemorrhages, cotton wool spots, and papilledema, according to the European Heart Journal 2
Thrombotic microangiopathy may occur, characterized by hemolysis, elevated enzyme levels, and thrombocytopenia, as stated by the European Heart Journal 2
Hypertensive encephalopathy may present with seizures, lethargy, cortical blindness, and coma, as reported by the European Heart Journal 2
Acute renal failure is common and prognostically important, according to the European Heart Journal 3

Patients with malignant hypertension should be admitted for close monitoring and treatment with intravenous BP-lowering agents, as recommended by the European Society of Cardiology 1
Target blood pressure reduction: Mean arterial pressure should be reduced by 20-25% within several hours, according to the European Heart Journal 1, 4
Avoid excessive or rapid reductions in blood pressure as this can lead to underperfusion of vital organs and complications, as stated by the European Heart Journal 3, 5

Labetalol is recommended as first-line intravenous therapy for malignant hypertension, as stated by the European Society of Cardiology 1, 4
Nicardipine is an effective alternative, administered by slow continuous infusion, according to the European Heart Journal 4

Sodium nitroprusside can be used as an alternative but requires careful monitoring due to risk of toxicity, as reported by the European Heart Journal 4
Urapidil is another alternative agent mentioned in European guidelines, according to the European Heart Journal 4
Clevidipine, an ultra-short acting calcium-channel blocker, may be used but is not widely available, as stated by the European Heart Journal 4

In patients with autonomic hyperreactivity, treatment with benzodiazepines should be initiated first, as recommended by the European Society of Cardiology 6
For patients with coronary ischemia, nitroglycerin and aspirin are recommended in addition to BP management, according to the European Heart Journal 6
In patients with pheochromocytoma, labetalol should be avoided as it may accelerate hypertension, and phentolamine, nitroprusside, or urapidil are preferred, as stated by the European Heart Journal 6

After initial stabilization with IV medications, transition to oral antihypertensive therapy should be initiated, as recommended by the European Society of Cardiology 1
Oral medications may include ACE inhibitors, but must be started at very low doses to prevent sudden decreases in BP, according to the European Heart Journal 4
Patients are often volume depleted due to pressure natriuresis, so careful fluid management is essential, as stated by the European Heart Journal 4

Patients who have experienced malignant hypertension remain at increased risk of cardiovascular and renal disease, as reported by the European Society of Cardiology 6
Key prognostic factors include elevated cardiac enzyme levels and renal impairment at presentation, according to the European Heart Journal 6
BP control and amount of proteinuria during follow-up are the main risk factors for renal survival, as stated by the European Heart Journal 6
Improving medication adherence is crucial, as non-adherence is a common precipitating factor, according to the European Heart Journal 6